top of page
road-map (1).png

Development Pipeline

Our pipeline

ACT225 BioTx is developing a proprietary pipeline of paired therapy (Tx) and diagnostic agents (Dx) against various solid tumors.

​

Discovery            Preclinical validation      Clinical trial-enabling           Phase 1          Phase 2

ACT225 Tx01/Dx01
Disease sites: Colorectal, triple-negative breast cancer
Pipeline-Line1.png
ACT225 Tx02/Dx02
Disease sites: non-small cell lung cancer, triple-negative breast cancer
Pipeline-Line2.png
​ACT225 Tx03/Dx03
Disease sites: pancreatic cancer, epithelial ovarian cancer
Pipeline-Line3.png
ACT225 Tx04/Dx04
Disease sites: breast cancer, gastric cancer
Pipeline-Line4.png
ACT225 Tx05/Dx05
Disease sites: lung adenocarcinoma, salivary gland cancer, pancreatic ductal adenocarcinoma
Pipeline-Line5.png
ACT225 Tx06/Dx06
Disease sites: prostate cancer
Pipeline-Line6.png
bottom of page